Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

135.54 -0.91 (-0.67%)
Streaming Delayed Price Updated: 3:51 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
ABBOTT LABORATORIES (NYSE:ABT) – A Quality Stock Worth Considering
ABBOTT LABORATORIES (NYSE:ABT) meets key quality investing criteria with strong revenue growth, high ROIC, and solid financial health, making it a stock worth considering for long-term portfolios. 
Via Chartmill
5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Steady growth and dividend increases over decades can make investors remarkably wealthy. 
Via The Motley Fool
Topics Economy
Exposures Economy
Tandem Diabetes Inks Deal With Abbott For New Diabetes Solutions: Retail Sentiment Stays Subdued
The agreement is to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with San Diego, California- based Tandem's innovative insulin... 
Via Stocktwits
3 Low-Volatility Stocks in Hot Water
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
Peering Into Abbott Laboratories's Recent Short Interest
Via Benzinga
1 Mooning Stock with Exciting Potential and 2 to Think Twice About
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions. 
Via StockStory
ABBOTT LABORATORIES (NYSE:ABT) - A Strong Technical Setup for Breakout Investors
ABBOTT LABORATORIES (NYSE:ABT) shows strong technicals and a high-quality setup, making it a potential breakout candidate for traders. 
Via Chartmill
3 Stocks With 3% to 9% Yields Just Raised Dividends Again
Via MarketBeat
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges
Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral. 
Via Benzinga
How Boston Scientific's Surprise Setback Bolstered Edwards, Medtronic, Abbott
The company said the regulatory path forward for one of its key systems is too murky to pursue. 
Via Investor's Business Daily
Exposures Product Safety
2 Dividend Stocks to Buy With $500 and Hold Forever
Via The Motley Fool
ABBOTT LABORATORIES (NYSE:ABT) – A Quality Stock Worth Considering
ABBOTT LABORATORIES (NYSE:ABT) meets key quality investing criteria with strong revenue growth, high ROIC, and excellent profit quality, making it a solid long-term candidate. 
Via Chartmill
3 Magnificent Stocks That Are Passive Income Machines
Via The Motley Fool
What's going on in today's session: S&P500 movers
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session. 
Via Chartmill
Recent Filing Shows That Rep. Bruce Westerman Sold Over $137K Worth of Apple Stock
Via Benzinga
ABBOTT LABORATORIES (NYSE:ABT) - A Strong Technical Setup for Breakout Investors
ABBOTT LABORATORIES (NYSE:ABT) shows strong technicals and a high-quality breakout setup, supported by institutional interest and clear support/resistance levels. 
Via Chartmill
Reflecting On Medical Devices & Supplies - Diversified Stocks’ Q1 Earnings: Abbott Laboratories (NYSE:ABT)
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Abbott Laboratories... 
Via StockStory
1 Mega-Cap Stock Worth Your Attention and 2 to Keep Off Your Radar
"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their... 
Via StockStory
Jensen Huang, Magic Johnson, Patrick Dempsey, Linda Yaccarino And More Bigwigs Headline Milken Global Conference 2025: What You Need To Know
The Milken Institute's 28th annual Global Conference, featuring prominent figures like Jensen Huang, Magic Johnson, and Linda Yaccarino, is focusing on key global issues such as AI, healthcare, and... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Here Are All the Dividend Kings Beating the S&P 500 in 2025 -- and the 2 That Are the Best Stocks to Buy Now
Via The Motley Fool
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
2 Stocks, 2 Decades, $200. Is This the Long-Term Dividend Play for Your Portfolio?
Via The Motley Fool
If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?
Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year? 
Via Investor's Business Daily
Topics Animal Testing Economy Government
Exposures Animal Testing Economy Political
Abbott Laboratories (NYSE:ABT) Shows Strong Technical Breakout Potential
Abbott Laboratories (NYSE:ABT) Shows Strong Technical Breakout Potential 
Via Chartmill
A Look Into Abbott Laboratories Inc's Price Over Earnings
Via Benzinga
3 Dividend Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
Exposures COVID-19
If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
AbbVie is well-positioned for industry-leading growth, as Skyrizi and Rinvoq sales outperform, driving system-wide growth alongside a diversified portfolio. 
Via MarketBeat
What To Expect From Penumbra’s (PEN) Q1 Earnings
Medical device company Penumbra (NYSE:PEN) will be reporting results tomorrow after the bell. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Earnings To Watch: ResMed (RMD) Reports Q1 Results Tomorrow
Medical device company ResMed (NYSE:RMD) will be announcing earnings results tomorrow after market close. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
What To Expect From Boston Scientific’s (BSX) Q1 Earnings
Medical device company Boston Scientific (NYSE:BSX) will be reporting results tomorrow before market open. Here’s what to look for. 
Via StockStory
Topics Economy
Exposures Interest Rates
Earnings To Watch: Intuitive Surgical (ISRG) Reports Q1 Results Tomorrow
Medical technology company Intuitive Surgical (NASDAQ:ISRG) will be reporting results tomorrow after market close. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.